Background and purpose: PET imaging of cetuximab uptake may help selecting cancer patients with the highest chance of benefit. The aim of this phase I trial was to determine the safety of the tracer (89)zr-cetuximab and to assess tumour uptake.Methods: Two dose schedules were used; two consecutive doses of 60 MBq Zr-89-cetuximab or a single dose of 120 MBq, both preceded by 400 mg/m(2) of unlabelled cetuximab. Toxicity (CTCAE 3.0) was scored twice weekly. PET-CT scans were acquired on days 4, 5 and 6 (step 1) or 5, 6, 7 (step 2). Because tumour uptake could not be assessed satisfactorily, a third step was added including EGFR overexpressing tumours.Results: Nine patients were included (6 NSCLC; 3 HNC). No additional toxicity was associated ...
Purpose: One-third of patients with RAS wild-type mCRC do not benefit from anti-EGFR monoclonal anti...
Contains fulltext : 219439.pdf (Publisher’s version ) (Open Access)PURPOSE: One-th...
Immunotherapy has improved the survival of patients with advanced stages of various cancers, however...
Background and purpose: PET imaging of cetuximab uptake may help selecting cancer patients with the ...
Background and purpose: PET imaging of cetuximab uptake may help selecting cancer patients with the ...
Biomarkers predicting treatment response to the monoclonal antibody cetuximab in locally advanced he...
Purpose One-third of patients with RAS wild-type mCRC do not benefit from anti-EGFR monoclonal antib...
Biomarkers predicting treatment response to the monoclonal antibody cetuximab in locally advanced he...
Biomarkers predicting treatment response to the monoclonal antibody cetuximab in locally advanced he...
Biomarkers predicting treatment response to the monoclonal antibody cetuximab in locally advanced he...
PURPOSE: In-vivo quantification of tumor uptake of 89-zirconium (89Zr)-labelled monoclonal antibodie...
Purpose: One-third of patients with RAS wild-type mCRC do not benefit from anti-EGFR monoclonal anti...
Contains fulltext : 219439.pdf (Publisher’s version ) (Open Access)PURPOSE: One-th...
Immunotherapy has improved the survival of patients with advanced stages of various cancers, however...
Background and purpose: PET imaging of cetuximab uptake may help selecting cancer patients with the ...
Background and purpose: PET imaging of cetuximab uptake may help selecting cancer patients with the ...
Biomarkers predicting treatment response to the monoclonal antibody cetuximab in locally advanced he...
Purpose One-third of patients with RAS wild-type mCRC do not benefit from anti-EGFR monoclonal antib...
Biomarkers predicting treatment response to the monoclonal antibody cetuximab in locally advanced he...
Biomarkers predicting treatment response to the monoclonal antibody cetuximab in locally advanced he...
Biomarkers predicting treatment response to the monoclonal antibody cetuximab in locally advanced he...
PURPOSE: In-vivo quantification of tumor uptake of 89-zirconium (89Zr)-labelled monoclonal antibodie...
Purpose: One-third of patients with RAS wild-type mCRC do not benefit from anti-EGFR monoclonal anti...
Contains fulltext : 219439.pdf (Publisher’s version ) (Open Access)PURPOSE: One-th...
Immunotherapy has improved the survival of patients with advanced stages of various cancers, however...